- Glucagon-like peptide 1 (GLP-1) receptor agonists do not appear to increase the risk for diabetic retinopathy based on a large database analysis of over 370,000 patients.
- A study led by Dr. Andrew Barkmeier found no increased risk of sight-threatening retinopathy in patients using GLP-1 medications compared to other glucose-lowering agents.
- The study also showed that patients using sodium-glucose cotransporter 2 (SGLT2) inhibitors had a lower risk of sight-threatening retinopathy compared to other drug classes.
- Previous concerns about diabetic retinopathy risks from GLP-1 agents were raised by a clinical trial, but this new study provides more reassuring results.
- The findings give retina specialists more confidence in advising patients on diabetes medications, with SGLT2 inhibitors appearing slightly safer for progression of diabetic retinopathy.
Source link
Ophthalmology, Diabetes & Endocrinology